PT1618195E - Método para inibição selectiva do gene n-myc humano em tumores expressando n-myc, através de ácidos nucleicos peptídicos (pna) anti-sentido e sentido - Google Patents

Método para inibição selectiva do gene n-myc humano em tumores expressando n-myc, através de ácidos nucleicos peptídicos (pna) anti-sentido e sentido Download PDF

Info

Publication number
PT1618195E
PT1618195E PT04730318T PT04730318T PT1618195E PT 1618195 E PT1618195 E PT 1618195E PT 04730318 T PT04730318 T PT 04730318T PT 04730318 T PT04730318 T PT 04730318T PT 1618195 E PT1618195 E PT 1618195E
Authority
PT
Portugal
Prior art keywords
myc
sense
nucleic acids
antisense
pepptido
Prior art date
Application number
PT04730318T
Other languages
English (en)
Inventor
Roberto Tonelli
Raffaele Fronza
Andrea Pession
Stefano Sforza
Roberto Corradini
Rosangela Marchelli
Original Assignee
Univ Parma
Univ Bologna Alma Mater
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Parma, Univ Bologna Alma Mater filed Critical Univ Parma
Publication of PT1618195E publication Critical patent/PT1618195E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
PT04730318T 2003-04-29 2004-04-29 Método para inibição selectiva do gene n-myc humano em tumores expressando n-myc, através de ácidos nucleicos peptídicos (pna) anti-sentido e sentido PT1618195E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000860A ITMI20030860A1 (it) 2003-04-29 2003-04-29 Metodo per l'inibizione selettiva del gene n-myc

Publications (1)

Publication Number Publication Date
PT1618195E true PT1618195E (pt) 2008-06-24

Family

ID=33398059

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04730318T PT1618195E (pt) 2003-04-29 2004-04-29 Método para inibição selectiva do gene n-myc humano em tumores expressando n-myc, através de ácidos nucleicos peptídicos (pna) anti-sentido e sentido

Country Status (12)

Country Link
US (1) US7947657B2 (pt)
EP (1) EP1618195B1 (pt)
JP (1) JP4719670B2 (pt)
AT (1) ATE389017T1 (pt)
CA (1) CA2522890C (pt)
DE (1) DE602004012404T2 (pt)
DK (1) DK1618195T3 (pt)
ES (1) ES2303636T3 (pt)
IT (1) ITMI20030860A1 (pt)
PL (1) PL1618195T3 (pt)
PT (1) PT1618195E (pt)
WO (1) WO2004096826A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019430A2 (en) * 2004-04-20 2006-02-23 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20100136526A1 (en) 2005-12-26 2010-06-03 Takumi Era Therapeutic Agent for Neuroblastoma Targeting ARID3b
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
US11827884B2 (en) 2017-05-15 2023-11-28 University Of Florida Research Foundation, Incorporated Core master regulators of glioblastoma stem cells

Also Published As

Publication number Publication date
EP1618195B1 (en) 2008-03-12
CA2522890C (en) 2013-07-02
US7947657B2 (en) 2011-05-24
ES2303636T3 (es) 2008-08-16
WO2004096826A3 (en) 2005-05-26
US20070020632A1 (en) 2007-01-25
DK1618195T3 (da) 2008-07-07
JP2006525010A (ja) 2006-11-09
JP4719670B2 (ja) 2011-07-06
ITMI20030860A1 (it) 2004-10-30
WO2004096826A2 (en) 2004-11-11
DE602004012404D1 (de) 2008-04-24
ATE389017T1 (de) 2008-03-15
CA2522890A1 (en) 2004-11-11
PL1618195T3 (pl) 2008-09-30
DE602004012404T2 (de) 2009-03-26
EP1618195A2 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
WO2001048190A3 (en) Therapeutic uses of lna-modified oligonucleotides
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
WO2005002643A3 (en) Method and products for delivering biological molecules to cells using multicomponent nanostructures
EP1248794A4 (en) ANTISENSE MODULATION OF SMAD7 PROTEIN EXPRESSION
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
WO2007035474A3 (en) Transdermal delivery peptides and method of use thereof
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
DE60332363D1 (de) Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
Sikora et al. Loss of transcription factor AP-1 DNA binding activity during lymphocyte aging in vivo
PL1618195T3 (pl) Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe
GB0418388D0 (en) Cell therapy
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
MXPA05006034A (es) Proteina de duplicacion.
TW200724679A (en) Treatment of disease using an improved regulated expression system
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
EP1322658A4 (en) OLIGONUCLEOTIDE MODULATION OF HER-1 RECEPTOR EXPRESSION
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
CN103597075A (zh) 用于选择性地杀伤细胞的生物活性核苷酸分子、其用途及应用试剂盒
WO2002046367A3 (en) Antisense modulation of cellular apoptosis susceptibility gene expression
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system